Where can I buy Vertex Pharmaceuticals (VRTX) stock?
Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vertex Pharmaceuticals' stock price today?
How much is a share of vertex worth?
One share of VRTX stock can currently be purchased for approximately $234.06. How much money does Vertex Pharmaceuticals make? Vertex Pharmaceuticals has a market capitalization of $59.51 billion and generates $6.21 billion in revenue each year.
When is Vertex Pharmaceuticals'next quarterly earnings announcement?
Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, February 7th 2022. View our earnings forecast for Vertex Pharmaceuticals. How were Vertex Pharmaceuticals' earnings last quarter?
Is Vertex Pharmaceuticals a buy for trikafta's threats?
Vertex Pharmaceuticals (NASDAQ: VRTX) is the leader in cystic fibrosis (CF) treatments. Gains were led by its blockbuster Trikafta. The only threat to Trikafta's market share is another Vertex candidate in development.
See more
Is VRTX a buy or sell?
The consensus among 13 Wall Street analysts covering (NASDAQ: VRTX) stock is to Buy VRTX stock.
What does VRTX make?
Vertex is in the business of discovering, developing, and commercializing small-molecule drugs for the treatment of serious genetic diseases including cystic fibrosis.
What is VRTX price target?
Stock Price Target VRTXHigh$368.00Median$291.00Low$240.00Average$297.87Current Price$292.84
Does Vertex Pharmaceuticals pay a dividend?
VRTX Vertex Pharmaceuticals Incorporated VRTX does not currently pay a dividend.
Is Vertex Big Pharma?
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry....Vertex Pharmaceuticals.TypePublic companyRevenueUS$3.04 billion (2018)Number of employees3,900Websitevrtx.com7 more rows
Is Vertex Pharmaceuticals a good company?
Vertex Pharmaceuticals has an overall rating of 4.2 out of 5, based on over 824 reviews left anonymously by employees. 83% of employees would recommend working at Vertex Pharmaceuticals to a friend and 85% have a positive outlook for the business. This rating has improved by 9% over the last 12 months.
Will VRTX go up?
Based on our forecasts, a long-term increase is expected, the "VRTX" stock price prognosis for 2027-07-09 is 371.008 USD. With a 5-year investment, the revenue is expected to be around +29.61%. Your current $100 investment may be up to $129.61 in 2027. Get It Now!
Will CRSP stock go up?
Stock Price Forecast The 22 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 108.50, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +31.66% increase from the last price of 82.41.
Is Vertex a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Should I buy or sell Vertex Pharmaceuticals stock right now?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 7 h...
What is Vertex Pharmaceuticals' stock price forecast for 2022?
15 brokers have issued 12-month price targets for Vertex Pharmaceuticals' shares. Their VRTX stock forecasts range from $222.00 to $350.00. On aver...
How has Vertex Pharmaceuticals' stock performed in 2022?
Vertex Pharmaceuticals' stock was trading at $219.60 at the start of the year. Since then, VRTX shares have increased by 16.1% and is now trading a...
When is Vertex Pharmaceuticals' next earnings date?
Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast f...
How were Vertex Pharmaceuticals' earnings last quarter?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings data on Thursday, May, 5th. The pharmaceutical company reported $3....
What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?
Vertex Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, May, 23rd. The company provided earnings per share (EPS) guidan...
Who are Vertex Pharmaceuticals' key executives?
Vertex Pharmaceuticals' management team includes the following people: Dr. Reshma Kewalramani FASN , M.D., CEO, Pres & Director (Age 49, Pay $4....
What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?
31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com . Reshma Kewalramani has an approval rating of 76% among Ve...
Who are some of Vertex Pharmaceuticals' key competitors?
Some companies that are related to Vertex Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Regeneron Pharmaceuticals (REGN) , Bi...
Is Vertex Pharmaceuticals stock a Buy, Sell or Hold?
Vertex Pharmaceuticals stock has received a consensus rating of buy. The average rating score is and is based on 31 buy ratings, 20 hold ratings, a...
What was the 52-week low for Vertex Pharmaceuticals stock?
The low in the last 52 weeks of Vertex Pharmaceuticals stock was 176.60. According to the current price, Vertex Pharmaceuticals is 144.33% away fro...
What was the 52-week high for Vertex Pharmaceuticals stock?
The high in the last 52 weeks of Vertex Pharmaceuticals stock was 292.75. According to the current price, Vertex Pharmaceuticals is 87.06% away fro...
What are analysts forecasts for Vertex Pharmaceuticals stock?
The 54 analysts offering price forecasts for Vertex Pharmaceuticals have a median target of 264.09, with a high estimate of 347.00 and a low estima...
When will Vertex Pharmaceuticals buy back its stock?
How much does Vertex Pharmaceuticals make?
How will Vertex Pharmaceuticals' stock buyback program work? Vertex Pharmaceuticals declared that its board has approved a stock repurchase program on Wednesday, July 31st 2019 , which authorizes the company to buyback $500,000,000.00 in shares, according to EventVestor.
What is Vertex Pharmaceuticals?
Vertex Pharmaceuticals has a market capitalization of $51.90 billion and generates $6.21 billion in revenue each year. The pharmaceutical company earns $2.71 billion in net income (profit) each year or $9.03 on an earnings per share basis.
What time do you trade in the pre market?
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally.
Does market cap include convertible securities?
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
What is Vertex Pharmaceuticals?
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Is ZacksTrade a separate company?
Boston, MA-based Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company’s main area of focus is cystic fibrosis (CF).#N#The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor/ivacaftor and ivacaftor), Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat around half of the 83,000 people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment ...